Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence